Nutlin-3

Catalog No.S1061

Nutlin-3 Chemical Structure

Molecular Weight(MW): 581.5

Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.

Size Price Stock Quantity  
In DMSO USD 185 In stock
USD 110 In stock
USD 170 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 12 Publications

5 Customer Reviews

  •  

    p53 activation in A76T p53-mutated UKF-NB-3’RITA(10 uM) IV cells. Cells were treated with RITA (10 uM) or nutlin-3 (10 uM) for 24 h and investigated by western blot for the expression of p53 target genes

    Cell Death Dis 2012 3, e294. Nutlin-3 purchased from Selleck.

    Caspase 3/7 activation in UKF-NB-3 or UKF-NB-3rNutlin10 μM cells treated nutlin-3 (10 μM), VCR (10 ng/ml), DOX (20 ng/ml), or CDDP (1000 ng/ml).

    Cell Death Dis 2011 2, e243. Nutlin-3 purchased from Selleck.

  • J Cell Physiol, 2018, 233(9):7424-7434. Nutlin-3 purchased from Selleck.

    Ubiquitination of p53 in vivo by BIRC6 in the presence of Nutlin-3. Cells were treated with Nutlin-3 (20 uM, 24 h) before harvest. Cell lysates were immunoprecipitated with anti-p53 antibody and immunoblotted by anti-ubiquitin antibody.

    Int J Oncol 2014 44, 761-8. Nutlin-3 purchased from Selleck.

  • d qPCR evaluation of DKK1 in MSCs exposed to melphalan in combination with increasing concentrations of nutlin-3 for 24 h. Cells were pre-treated with nutlin-3 for 20 min prior to chemotherapy. *Indicates p value<0.05, One-way ANOVA with Holm-Sidak post hoc

    Med Oncol, 2016, 33(10):113. Nutlin-3 purchased from Selleck.

Purity & Quality Control

Choose Selective Mdm2 Inhibitors

Biological Activity

Description Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.
Targets
Mdm2 [5]
(Cell-free assay)
180 nM
In vitro

Nutlin-3 potently inhibits the MDM2-p53 interaction, leading to the activation of the p53 pathway. Nutlin-3 treatment induces the expression of MDM2 and p21, and displays potent antiproliferative activity with IC50 of ~1.5 μM, only in cells with wild-type p53 such as HCT116, RKO and SJSA-1, but not in the mutant p53 cell lines SW480 and MDA-MB-435. In SJSA-1 cells, Nutlin-3 treatment at 10 μM for 48 hours significantly induces caspase-dependent cell apoptosis by ~45%. Although Nutlin-3 also inhibits the growth and viability of human skin (1043SK) and mouse embryo (NIH/3T3) with IC50 of 2.2 μM and 1.3 μM, respectively, cells remain viable 1 week post-treatment even at 10 μM of Nutlin-3, in contrast with the SJSA-1 cells with viability lost at 3 μM of Nutlin-3 treatment. [1] Nutlin-3 does not induce the phosphorylation of p53 on key serine residues and reveals no difference in their sequence-specific DNA binding and ability to transactivate p53 target genes compared with phosphorylated p53 induced by the genotoxic drugs doxorubicin and etoposide, demonstrating that phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. [2] Although binding less efficiently to MDMX than to MDM2, Nutlin-3 can block the MDMX–p53 interaction and induce the p53 pathway in retinoblastoma cells (Weri1) with IC50 of 0.7 μM. [3] Nutlin-3 at 30 μM also disrupts endogenous p73-HDM2 interaction and enhances the stability and proapoptotic activities of p73, leading to the dose-dependent cell growth inhibition and apoptosis induction in cells without wild-type p53. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 M33LXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NID6NXk2yqEQvF2= NGWwRlk1QMLiaB?= Mo[zZoxw[2u|IEK3MW9JSy2rbnT1Z4VlKGOnbHygdJJwdGmoZYLheIlwdiClb33wZZJi[mynIITvJJRp[XRib3[gZoF{[WxibHX2[Yx{ NXixc2tCOjZ|NUC1OlU>
NP69 NF\3PHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\MZplKSzVyPUOxMlY6yrF{LkW0JO69VQ>? MlG1NlYzPTJ3N{W=
NP460 M3:yZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfXU2ZzUUN3ME2yNk45PcLzMT6xPEDPxE1? NXuxU4pEOjZ{NUK1O|U>
C666-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zab2lEPTB;MUmuPVXDuThwOUOg{txO M4izdVI3OjV{NUe1
C666-1 M4HXZWNmdGxiVnnhZoltcXS7IFHzd4F6 NWi1bHBLOTBiwsXN MmnJOFghcA>? M4TYWWROW09? NXv5TFFoe2Wwc3n0bZpmeyCFNk[2MVEh[2WubIOgeI8hfGinIHP5eI91d3irYzDl[oZm[3Rib3[gZ4l{eGyjdHnu MlvwNlYzPTJ3N{W=
C666-1  M3S0d2Z2dmO2aX;uJGF{e2G7 NYLhZY5[OTBiwsXN NYDQOmp7OjRiaB?= Ml\RSG1UVw>? MofjZYN1cX[jdHXzJJRp\SCyNUOgdIF1cHejeTygeZBz\We3bHH0bY5oKHB3MzygdFIyKGGwZDDN[I0z MofQNlYzPTJ3N{W=
C666-1 MWnBdI9xfG:|aYOgRZN{[Xl? MmDqNVAhyrWP NWLtcGtCPDhxN{KgbC=> NXvSW3VmTE2VTx?= NHTuWlR{\W6|aYTpfoV{KEN4Nk[tNUBk\WyuczD0c{BkcXOybHH0bY4ucW6mdXPl[EBieG:ydH;zbZM> MoLZNlYzPTJ3N{W=
A549 NV\XdmlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HGcFI1KGh? M3rHR2lEPTB;MUeuOlghyrFiND61NkDPxE1? NFfYVlgzPjF{NUKzNC=>
A549-NTC Mn\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPJ[W8zPCCq NXrwVZdMUUN3ME2xPU41OiEEsTCxMlk3KM7:TR?= NIXYUmEzPjF{NUKzNC=>
A549-920 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYKyOEBp NX;hT5A{UUN3ME2zN{45PSEEsTC0Mlg1KM7:TR?= MWWyOlEzPTJ|MB?=
CRL-5908 M3\QbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1P0elI1KGh? MXrJR|UxRTN6LkexJOKyKDJwNEOg{txO NXm1fpExOjZzMkWyN|A>
L6 NH3nXVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1v5bVExyqEQvF5CpC=> MYWyOE81QC95MjDo MmHqSG1UVw>? NIX3XHNqdmirYnn0d{Bk\WyuczDwdo9tcW[ncnH0bY9vKGGwZDDkbYZn\XKnboTpZZRqd25? NW\qN29QOjV6N{G3PVQ>
C2C12 M{O2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XTdlExyqEQvF5CpC=> MkXrNlQwPDhxN{KgbC=> M{L0VmROW09? M3foOIlvcGmkaYTzJINmdGy|IIDyc4xq\mW{YYTpc44h[W6mIHTp[oZmemWwdHnheIlwdg>? NUKyfGp1OjV6N{G3PVQ>
MCF-7  NYqzUI1RTnWwY4Tpc44hSXO|YYm= NFfQRnkyOMLizszN MVLEUXNQ MoTtbY5pcWKrdIOgZ5lkdGmwIFSxJIFv\CCGaXPlduKh MYOyOVcxOjdyMx?=
DU4475  NEftWWRHfW6ldHnvckBCe3OjeR?= MXK1M|ExNzJyIN88US=> NVz6[nh7OjUEoHi= NIXHS2xld3ewcnXneYxifGW|IGTvZ4EuOSCmb4PlJIRmeGWwZHXueIx6 M2TjUVI2PTR5MUe0
SMMC-7721 NVfhRpg5TnWwY4Tpc44hSXO|YYm= NF;afWMyOCEQvF2= MYi0PEBp MXfEUXNQ M4XyOoNifXOnczDEUmEhTFOEIHThcYFo\Q>? NGnwXJUzPTV2NEO2NS=>
SMMC-7721 NWPLNo9UTnWwY4Tpc44hSXO|YYm= NVnXXGJOOTBizszN MWK0PEBp MWPEUXNQ M1rVeolv\HWlZYOgeIhmKGOqcn;tZZRqdi2kb4Xu[EBxem:2ZXnuJGlHUTF4IITvJJBienSrYXzsfUBtd2OjbHn6[UBqdiC2aHWgZ5l1d3CuYYPtxsA> NETVUo0zPTV2NEO2NS=>
SMMC-7721 NIDLTmtHfW6ldHnvckBCe3OjeR?= MnPrNVAh|ryP M2frPFQ5KGh? NHLCc4JFVVOR Moi1bY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:owrDJSm5DOcLibWLORS=> MXuyOVU1PDN4MR?=
SMMC-7721 MoXWSpVv[3Srb36gRZN{[Xl? M3\qZ|ExKM7:TR?= M3jUNVM3KGh? MlfCSG1UVw>? NHnOS3Bk[XW|ZYOgeIhmKGWldH;wbYMh\XiycnXzd4lwdiCxZjDJSmkyPg>? MXWyOVU1PDN4MR?=
MCF-7 NEnveWFHfW6ldHnvckBCe3OjeR?= MUmxNOKh|ryP M{XHVVAuOjRiaB?= MnHsbY5lfWOnczDwOVMh[W6mIICyNU9EcXBz NUP6fW4zOjV2OEKzO|M>
OVCAR10 NHTYW2NHfW6ldHnvckBCe3OjeR?= MnT3NVDDqM7:TR?= MYmyNYjDqA>? MmjjSG1UVw>? MX\pcoNz\WG|ZYOgdFU{KHC{b4TlbY4hdGW4ZXzz MoDHNlU1OjZ3NEi=
NCI-H23 MWDGeY5kfGmxbjDBd5NigQ>? M1X4cVExyqEQvF2= M3nPTVIycMLi NWXmR4l[TE2VTx?= M3XCUolv[3KnYYPld{BxPTNicILveIVqdiCuZY\lcJM> M3nJXlI2PDJ4NUS4
A2780 MULGeY5kfGmxbjDBd5NigQ>? NGO2RVkyOMLizszN NHT0OnIzOWkEoB?= MnzYSG1UVw>? MWrpcoNz\WG|ZYOgdFU{KHC{b4TlbY4hdGW4ZXzz Ml6zNlU1OjZ3NEi=
NCI-H23 M{T3bmZ2dmO2aX;uJGF{e2G7 NXu0NHd6OTEEoN88US=> Mmj6NlFpyqB? NHvQc3lFVVOR NWPTU452\GWlcnXhd4V{KHSqZTDGc5hOOSCuZY\lcJM> M3X0UFI2PDJ4NUS4
A2780 M2r1cWZ2dmO2aX;uJGF{e2G7 MXixNOKh|ryP MVeyNYjDqA>? MlHGSG1UVw>? MY\k[YNz\WG|ZYOgeIhmKE[xeF2xJIxmfmWucx?= MmTuNlU1OjZ3NEi=
HCT116  MUDGeY5kfGmxbjDBd5NigQ>? NEWzSHAyOCEEtV2= MVqyOEBp MU\jZZV{\XNiYTDwOVMu\GWyZX7k[Y51KHSndILhdIxwcWRiR{GtZZJz\XO2IHnuJIRqeGyxaXSgTGNVOTF4IHPsc45meyCGMzDhcoQhTDh? M{KzTlI2OzhyMEW1
MCF-10CA1a M2\4TWZ2dmO2aX;uJGF{e2G7 NUL0XHo{OTEEoN88US=> Mlm1OFghcA>? MYPEUXNQ NY\HZmVwcW6qaXLpeJMh[mG|YXygbY53[XOrb36gZY5lKHKnZIXj[YQhXEeILd8yN{1qdmS3Y3XkJIlvfmG|aX;uJJRwKGKjc3HsJIxmfmWucx?= MXmyOVI2Pzd{OR?=
MCF-10A1  NVfWe|A2TnWwY4Tpc44hSXO|YYm= MonKNVDDqM7:TR?= M1;VfFI1NzR6IHi= NW[3R4tXTE2VTx?= M1WyUYlvcGmkaYTzJI1q\3KjdHnvckBw\iCwb4LtZYwh[nKnYYP0JIVxcXSqZXzpZYzDqA>? MXGyOVI2Pzd{OR?=
MCF-10CA1a MmXHSpVv[3Srb36gRZN{[Xl? M1nFNVExyqEQvF2= NGXMdHYzPCCq NVTKVG9jTE2VTx?= NGLre5dl\WO{ZXHz[ZMhfGinIGTHSk3PujNvaX7keYNm\CCvUl7BJIxmfmWuczDv[m1OWDJuwrDNUXA6NCCjbnVCpIlvfGWpcnnuxsDPusLiMx?= Mo\oNlUzPTd5Mkm=
MCF-10CA1a M4fUPGZ2dmO2aX;uJGF{e2G7 NIfZTncyOMLizszN NInUVZozPCCq NFToNnBFVVOR MnPEbY5pcWKrdIOgJHRITi4QskOtbY5lfWOnZDDFVGhDOsLibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w M4jHNFI2OjV5N{K5
SK-BR-7 NYHTdWlETnWwY4Tpc44hSXO|YYm= NWTVZWZXOTEEoN88US=> MY[yOEBp M1LF[2ROW09? MkDibY5pcWKrdIOgJHRITi4QskOtbY5lfWOnZDDFVGhDOsLibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w M{LaXFI2OjV5N{K5
SUM102PT NUTWXnR1TnWwY4Tpc44hSXO|YYm= M{\HUVExyqEQvF2= NH7wbYYzPCCq M1zlPWROW09? MYDpcohq[mm2czCgWGdHNc7{Mz3pcoR2[2WmIFXQTGIzyqCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25? NX[4[3RXOjV{NUe3Nlk>
RAW 264.7 MlO4SpVv[3Srb36gRZN{[Xl? M2joNlExyqEQvF2= MlP6N|AhdWmw M1KwUZBz\X[nboTzJJRp\SCyNUOgdoVlfWO2aX;uJIlvKHKnc4DvcpNmKHSxIFzQVy=> MkPvNlUyPzJ3NEe=
RAW 264.7 NYPMcGpMTnWwY4Tpc44hSXO|YYm= M1nTNlExyqEQvF2= MXWzNEBucW5? M{\0[pJm\HWlZYOgeIhmKEySUz3heYdu\W62ZXSgeIhmKE6ILd86RkBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZYN1cX[rdIm= MVSyOVE4OjV2Nx?=
RAW 264.7 M{jh[mZ2dmO2aX;uJGF{e2G7 MUixNOKh|ryP M2C3SVMxKG2rbh?= MnHlbY5pcWKrdIOgUHBUNWmwZIXj[YQhVk9icILv[JVkfGmxbtMg MVuyOVE4OjV2Nx?=
MCF7  NHnQTpdE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NIn1NXAzNjViwsXN M{fvdVUh\A>? NXvmfYt7TE2VTx?= MX3z[Y5{cXSrenXzJG1ETjdidH:gVGFTWCCrbnjpZol1cW:w M37GT|I2ODh3OUCy
MCF7  NX73Z4JiTnWwY4Tpc44hSXO|YYm= MmjCNk42KML3TR?= MkfzOFghcA>? NXTGfGYzTE2VTx?= NHi1dYhl\WO{ZXHz[ZMhfGinIHjvcY9td2exdYOgSHNDKHKncHHpdkBnemWzdXXuZ4lmew>? M3H5R|I2ODh3OUCy
ACHN MYnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NIrwbFUxNjVvMUCg{txO NWjCV5AzOC14IHS= NFTaO4lFVVOR NXzlPGVKcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NIHuU3czPTB4N{e4Oy=>
Caki-2 Mm[zR4VtdCCYaXHibYxqfHliQYPzZZk> MWqwMlUuOTBizszN MkLRNE03KGR? M{nucWROW09? MX3pcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NV7mRm5jOjVyNke3PFc>
A498 NWX3[m1KS2WubDDWbYFjcWyrdImgRZN{[Xl? Mlm5NE42NTFyIN88US=> M4KzSlAuPiCm MlXjSG1UVw>? M{XybolvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M3vn[FI2ODZ5N{i3
115 NXnMSoJmS2WubDDWbYFjcWyrdImgRZN{[Xl? MWSwMlUuOTBizszN MXSwMVYh\A>? NX\WNpBJTE2VTx?= NXfWPHBkcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NFrWfZYzPTB4N{e4Oy=>
117 NVjL[I96S2WubDDWbYFjcWyrdImgRZN{[Xl? MWmwMlUuOTBizszN MmfyNE03KGR? NWDqdWZrTE2VTx?= NIjpXmlqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NVzBd|N{OjVyNke3PFc>
ACHN NGDsTJhHfW6ldHnvckBCe3OjeR?= NGHYU5QxNjVxMT:1JO69VQ>? MV60PEBp NEiwV2pFVVOR M2jnPIxm[WS|IITvJIlv[3KnYYPl[EBmgHC{ZYPzbY9vKG:oIIC1N{BidmRic3;t[UBxPTNidHHy[4V1KGenbnXzPkBOTE1{LDDhcoQheDJz M4LCe|I2ODZ5N{i3
Caki-2 MWjGeY5kfGmxbjDBd5NigQ>? MWKwMlUwOS93IN88US=> M1TVOFQ5KGh? M32yT2ROW09? M{exeYxm[WS|IITvJIlv[3KnYYPl[EBmgHC{ZYPzbY9vKG:oIIC1N{BidmRic3;t[UBxPTNidHHy[4V1KGenbnXzPkBOTE1{LDDhcoQheDJz Mm\xNlUxPjd5OEe=
A498 NULxSFRbTnWwY4Tpc44hSXO|YYm= NUnPU5RFOC53L{GvOUDPxE1? MXq0PEBp M4nIT2ROW09? M4nNfIxm[WS|IITvJIlv[3KnYYPl[EBmgHC{ZYPzbY9vKG:oIIC1N{BidmRic3;t[UBxPTNidHHy[4V1KGenbnXzPkBOTE1{LDDhcoQheDJz NXnJfmEyOjVyNke3PFc>
115 MnnKSpVv[3Srb36gRZN{[Xl? MojINE42NzFxNTFOwG0> M3n0XVQ5KGh? M{TJZmROW09? M{Dtd4xm[WS|IITvJIlv[3KnYYPl[EBmgHC{ZYPzbY9vKG:oIIC1N{BidmRic3;t[UBxPTNidHHy[4V1KGenbnXzPkBOTE1{LDDhcoQheDJz M2fycFI2ODZ5N{i3
ACHN NFnKe4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrYZZlJPSEQvF2= NUjpNHhrPDhiaB?= MXPEUXNQ MW\pcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2wrC= M1;UeFI2ODZ5N{i3
Caki-2 NFHrSINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWf4XWJwPSEQvF2= MW[0PEBp NUXSbIN1TE2VTx?= M2DUOIlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4VCpC=> MmH0NlUxPjd5OEe=
A498 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnBXGlGPSEQvF2= M2HGXFQ5KGh? NF7HZ4VFVVOR M4PMdolv\HWlZYOgZ4VtdCCleXPs[UBienKnc4VCpC=> NE\rU3czPTB4N{e4Oy=>
115 M13YfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TzR|Uh|ryP NInob4w1QCCq MnrISG1UVw>? MoPNbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dNMg MX2yOVA3Pzd6Nx?=
ACHN MnjFSpVv[3Srb36gRZN{[Xl? M120NFUh|ryP MnXKOFghcA>? NX3oVVdDTE2VTx?= MWDpcoR2[2W|IIC1N{1l\XCnbnTlcpQhe2WwZYPj[Y5k\cLi NIfrblMzPTB4N{e4Oy=>
Caki-2 NG\afmhHfW6ldHnvckBCe3OjeR?= NULRNHFkPSEQvF2= M13SPVQ5KGh? NHOz[HBFVVOR NWC4U|F3cW6mdXPld{BxPTNvZHXw[Y5l\W62IIPlcoV{[2WwY3ZCpC=> MVeyOVA3Pzd6Nx?=
A498 NELDTFBHfW6ldHnvckBCe3OjeR?= NYTZdGZUPSEQvF2= MXS0PEBp MXjEUXNQ MUPpcoR2[2W|IIC1N{1l\XCnbnTlcpQhe2WwZYPj[Y5k\cLi M3;CelI2ODZ5N{i3
115 M1PQWmZ2dmO2aX;uJGF{e2G7 M2jxb|Uh|ryP M{D1PFQ5KGh? M33Mc2ROW09? M1fBTIlv\HWlZYOgdFU{NWSncHXu[IVvfCC|ZX7ld4NmdmOnwrC= Mk\0NlUxPjd5OEe=
MOLM-13 NGHYfYVHfW6ldHnvckBCe3OjeR?= MnzkOuKh|ryP MojFNE05KGh? NU[3Z2w2TE2VTx?= M4rUO4lv[3KnYYPld{B1cGVibHX2[Yx{KG:oIIC1N{whVUSPMjygdFIyKGGwZDDhZ4V1gWyjdHXkJJA2Ow>? M2P1[VI1QDh3MEiy
MOLM-13 NGjJZ29HfW6ldHnvckBCe3OjeR?= Mlz3OuKh|ryP MUK2JIg> M{TLW2ROW09? MnzI[Y5p[W6lZYOgeIhmKGGlZYT5cIF1cW:wIH;mJIhqe3SxbnWgTFJDKGGwZDDo[YF1KHOqb3PrJJBzd3SnaX7zJGh{eDJ5IHHu[EBJe3B7MB?= NFKwZYEzPDh6NUC4Ni=>
HepG2 NEX3WINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF:0bXE4OiCq NELqZ2FFVVOR NXvvenpTUUN3ME2zOU45PiEEsTCyMlkh|ryP NYm2[Gt7OjR6OES4NFk>
HepG2/As NUPHd3JqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPVO|IhcA>? NFS0SVdFVVOR NV3TemVqUUN3ME22PE4yOyEEsTC5MlYh|ryP MYKyOFg5PDhyOR?=
SMMC7721 NYDBbWdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HBVFczKGh? NV6yUmZwTE2VTx?= NIDJTHBKSzVyPUOxMlI5KMLzIESuNkDPxE1? MYWyOFg5PDhyOR?=
SMMC7721/Ac NVrCfHpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nweVczKGh? MoLDSG1UVw>? MnfCTWM2OD13NT6yNUDDuSB3LkCzJO69VQ>? MXKyOFg5PDhyOR?=
Huh-7 NITtcXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVK3NkBp NFPsc|VFVVOR NEPzbIZKSzVyPUOzMlk3KMLzIEOuPUDPxE1? MmnkNlQ5QDR6MEm=
Hep3B M3GyWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnmfos4OiCq NVTsNGJNTE2VTx?= NYP4XFJLUUN3ME2yNE4yQCEEsTCxMlg1KM7:TR?= MnG3NlQ5QDR6MEm=
HepG2 M3HJfmFxd3C2b4Ppd{BCe3OjeR?= NWXCRolQcW6mdXPld{BieG:ydH;zbZM> M1npXVI1QDh2OEC5
SMMC7721 NYe1OZI5SXCxcITvd4l{KEG|c3H5 M{XadYlv\HWlZYOgZZBweHSxc3nz NXntXlZsOjR6OES4NFk>
Huh-7 NUfNcXZkSXCxcITvd4l{KEG|c3H5 MnfkbY5lfWOnczDhdI9xfG:|aYO= MVOyOFg5PDhyOR?=
Hep3B NHTGcYhCeG:ydH;zbZMhSXO|YYm= NYDqenpLcW6mdXPld{BieG:ydH;zbZM> NGG0NVEzPDh6NEiwPS=>
U2OS  NIHzbJhHfW6ldHnvckBCe3OjeR?= MVuyNEDPxE1? MV[yOEBp MYnpcoNz\WG|ZYOgeIhmKG2UTlGgcIV3\Wy|IH;mxsBDS0x{QUGsJGJEVFiOwrDhcoRDS0yZ NFP1SYszPDh4N{K1PS=>
AML2 MVjBdI9xfG:|aYOgRZN{[Xl? Ml3xNk8yOCEQvF2= NX3IN5o3OjRxNEigbC=> NVrwS5U1cW6mdXPld{BieG:ydH;zbZM> MXqyOFY2QTd2OR?=
MOML13 NETWUndCeG:ydH;zbZMhSXO|YYm= NHi4T3IzNzFyIN88US=> NX\JSXpMOjRxNEigbC=> MljzbY5lfWOnczDhdI9xfG:|aYO= MlrVNlQ3PTl5NEm=
AML2 Mnr1SpVv[3Srb36gRZN{[Xl? NYPFeWxpOTEQvF2= NUPHTYpDOi92IHi= NVniVYFDcW6lcnXhd4V{KHSqZTDs[ZZmdCCxZjDwOVM> MUCyOFY2QTd2OR?=
AML3 NFS5ZnZHfW6ldHnvckBCe3OjeR?= M3XvbVEx|ryP NIXlSmUzNzRiaB?= NWe4NopocW6lcnXhd4V{KHSqZTDs[ZZmdCCxZjDwOVM> NYXmNWk{OjR4NUm3OFk>
MOML13 MkjISpVv[3Srb36gRZN{[Xl? MlqxNVDPxE1? MnraNk81KGh? NX7zfGlScW6lcnXhd4V{KHSqZTDs[ZZmdCCxZjDwOVM> MXqyOFY2QTd2OR?=
BeWo NHrZRlZHfW6ldHnvckBCe3OjeR?= NHjVRYs{OCEEtV2= NEOxTHMzPCCq MVrpcoNz\WG|ZYOgdFU{NCCPZH2yMEBxOjFiYX7kJHB2dWFiYYSgeIhmKHC{b4TlbY4hdGW4ZXy= MYWyOFQ6QDF3NB?=
BeWo MV7BdI9xfG:|aYOgRZN{[Xl? NI[zdoQ{OCEEtV2= MYWyOEBp MVPpcoNz\WG|ZYOgZZBweHSxc3nz MXqyOFQ6QDF3NB?=
OCI Moq4SpVv[3Srb36gRZN{[Xl? MWKxNEDPxE1? NVXQT5FyOjRiaB?= M1\NeJVxemWpdXzheIV{KHSqZTDTU2NUNTFiZYjwdoV{e2mxbh?= Mk\INlQ1PzN3NkK=
MOLM M4WzZWZ2dmO2aX;uJGF{e2G7 NF7sUIUyOCEQvF2= Mk\xNlQhcA>? NWjiN|JQfXC{ZXf1cIF1\XNidHjlJHNQS1NvMTDlfJBz\XO|aX;u MoTxNlQ1PzN3NkK=
U2OS  NXLNN3EzTnWwY4Tpc44hSXO|YYm= MYCyNEDPxE1? NG\lZpczPCCq NIH0e2dqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjD0bIUhUE9vMTDwdo91\WmwIHHzJJdmdGxiYYOgeIhmKHB3MzDwdo91\Wmw NWL0V4tYOjR|Nk[wNFc>
RKO M{HBcmZ2dmO2aX;uJGF{e2G7 M1\SbFIxKM7:TR?= MVqyOEBp NXLLPWRGcW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[geIhmKEiRLUGgdJJwfGWrbjDhd{B4\WyuIHHzJJRp\SCyNUOgdJJwfGWrbh?= NXfKVVB2OjR|Nk[wNFc>
U2OS  NXe1RocyTnWwY4Tpc44hSXO|YYm= MlnONlAh|ryP MoDUNlQhcA>? NFHXZYdqdmS3Y3XzJGhQNTFiZYjwdoV{e2mxbjDheEB1cGVibHX2[Ywhd2ZidILhcpNkemmydHnvci=> MnHRNlQ{PjZyMEe=
RKO MVnGeY5kfGmxbjDBd5NigQ>? NX;FNlJGOjBizszN Mnz5NlQhcA>? MlTTbY5lfWOnczDIU{0yKGW6cILld5Nqd25iYYSgeIhmKGyndnXsJI9nKHS{YX7zZ5JqeHSrb36= NHvxZ3gzPDN4NkCwOy=>
SMMC-7721  MlHSR4VtdCCYaXHibYxqfHliQYPzZZk> M2DINFEvOjVvMkCg{txO NGTEc5AzPC92OD:3NkBp NGLPVFBFVVOR NVPhNGVxcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70cJk> M1T2PVI1Ojh4M{Gy
HuH-7 M1nKdGNmdGxiVnnhZoltcXS7IFHzd4F6 M2\UPFEvOjVvMkCg{txO M2CwXlI1NzR6L{eyJIg> MoS3SG1UVw>? MV;pcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36g[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnSueR?= MWWyOFI5PjNzMh?=
SMMC-7721  MlXCRZBweHSxc3nzJGF{e2G7 MXeyNEDPxE1? NUCzbZJuPDhiaB?= NGruUFdFVVOR NXv1elM2cW6mdXPld{BieG:ydH;zbZM> MXuyOFI5PjNzMh?=
HuH-7 NUHjbFg4SXCxcITvd4l{KEG|c3H5 MoLaNlAh|ryP NWL2[pZWPDhiaB?= MYjEUXNQ M371TYlv\HWlZYOgZZBweHSxc3nz MmDFNlQzQDZ|MUK=
SMMC-7721  MnrUSpVv[3Srb36gRZN{[Xl? MUWxNEDPxE1? MoXkN|YhcA>? MVnEUXNQ MVPkc5dvNXKnZ4XsZZRmeyC2aHWgdJJwfGWrbjDlfJBz\XO|aX;uJIxmfmWuIH;mJJBpd3OyaH:tV4VzOzl{LYC1Ny=> NUGydYJ5OjR{OE[zNVI>
HuH-7 MUXGeY5kfGmxbjDBd5NigQ>? MV2xNEDPxE1? M2fHSlM3KGh? MXPEUXNQ M{SwOoRwf25vcnXneYxifGW|IITo[UBxem:2ZXnuJIV5eHKnc4Ppc44hdGW4ZXygc4YheGixc4Doc{1U\XJ|OUKtdFU{ M3S1fVI1Ojh4M{Gy
AT2 MmL4SpVv[3Srb36gRZN{[Xl? NH2zcFg2NzFyIN88US=> NFf1d|dt\WGmczD0c{BiKHO3YoP0ZY51cWGuIHHjZ5VufWyjdHnvckBw\iC2aHWgdFU{KHC{b4TlbY4h[XNid3XscEBieyC2aHWg[ZhxemW|c3nvckBw\iCrdIOg[Ilz\WO2IIThdodmfHNicEKxMEBOTE1{IHHu[EB1cGVicILvMYFxd3C2b4TpZ{BDSVhiYX7kJHBWVUFicILveIVqdnQEoB?= NHvKfI0zPDJ2MEKwNy=>
REH NWCwbXpUTnWwY4Tpc44hSXO|YYm= NYPL[HltPS9zMDFOwG0> NEnleXZt\WGmczD0c{BiKHO3YoP0ZY51cWGuIHHjZ5VufWyjdHnvckBw\iC2aHWgdFU{KHC{b4TlbY4h[XNid3XscEBieyC2aHWg[ZhxemW|c3nvckBw\iCrdIOg[Ilz\WO2IIThdodmfHNicEKxMEBOTE1{IHHu[EB1cGVicILvMYFxd3C2b4TpZ{BDSVhiYX7kJHBWVUFicILveIVqdnQEoB?= M1fPOFI1OjRyMkCz
UoCB6 MYHGeY5kfGmxbjDBd5NigQ>? M{XBe|UwOTBizszN MUPs[YFleyC2bzDhJJN2[nO2YX70bYFtKGGlY4XteYxifGmxbjDv[kB1cGVicEWzJJBzd3SnaX6gZZMhf2WubDDhd{B1cGViZYjwdoV{e2mxbjDv[kBqfHNiZHny[YN1KHSjcnfleJMheDJzLDDNSG0zKGGwZDD0bIUheHKxLXHwc5B1d3SrYzDCRXgh[W6mIGDVUWEheHKxdHXpcpPDqA>? NG\iNHAzPDJ2MEKwNy=>
AT2 M2TJU2NmdGxiVnnhZoltcXS7IFHzd4F6 MYSwMVI2KM7:TR?= NYnlPJRqcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= M13xNFI1OjRyMkCz
REH MnuzR4VtdCCYaXHibYxqfHliQYPzZZk> MYqwMVI2KM7:TR?= NXfRem5mcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= MV[yOFI1ODJyMx?=
UoCB6 NHmwdJhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MkX1NE0zPSEQvF2= MYLpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NXXr[oZoOjR{NECyNFM>
A2780 M4nV[GZ2dmO2aX;uJGF{e2G7 NYrGc5NRPS9zMD:yNEDPxE1? MmPuNlQhcA>? NFTwTnh2eHKnZ4XsZZRmeyCyNUOsJG1FVTJuIICyNUBidmRiRGK1JJBzd3SnaX6gcIV3\Wy|IHTvd4Uh\GWyZX7k[Y51dHoEoB?= MlXXNlQyOzZzNEe=
H460 MoDnSpVv[3Srb36gRZN{[Xl? MXK1M|ExNzJyIN88US=> MVmyOEBp NFfrZph2eHKnZ4XsZZRmeyCyNUOsJG1FVTJuIICyNUBidmRiRGK1JJBzd3SnaX6gcIV3\Wy|IHTvd4Uh\GWyZX7k[Y51dHoEoB?= MUGyOFE{PjF2Nx?=
Lovo  M1O5WmZ2dmO2aX;uJGF{e2G7 NHK5[nM2NzFyL{KwJO69VQ>? MW[yOEBp M1nafJVxemWpdXzheIV{KHB3MzygUWROOixicEKxJIFv\CCGUkWgdJJwfGWrbjDs[ZZmdHNiZH;z[UBl\XCnbnTlcpRtgcLi NXLMT2wxOjRzM{[xOFc>
A2780 NIPTW4RCeG:ydH;zbZMhSXO|YYm= M2D5VlUwOTBxMkCg{txO NVy5NW51OjRiaB?= NYHUUIpC\W6qYX7j[ZMh[XCxcITvd4l{KGmwZIXjeIlwdiCkeTDENlY6UC:HMUm1VkBwfmW{IILoWHJCUUx? NEWye|AzPDF|NkG0Oy=>
H460 MXTBdI9xfG:|aYOgRZN{[Xl? NHzHUmI2NzFyL{KwJO69VQ>? NF;QXJEzPCCq NV3pc4hL\W6qYX7j[ZMh[XCxcITvd4l{KGmwZIXjeIlwdiCkeTDENlY6UC:HMUm1VkBwfmW{IILoWHJCUUx? M1ntOVI1OTN4MUS3
Lovo  M4nkdWFxd3C2b4Ppd{BCe3OjeR?= MknxOU8yOC9{MDFOwG0> NH;nSI4zPCCq NHXqWJhmdmijbnPld{BieG:ydH;zbZMhcW6mdXP0bY9vKGK7IFSyOllJN0VzOUXSJI93\XJicnjUVmFKVA>? NXfWN3V[OjRzM{[xOFc>

... Click to View More Cell Line Experimental Data

In vivo Oral administration of Nutlin-3 at 200 mg/kg twice daily for 3 weeks significantly inhibits the tumor growth of SJAS-1 xenografts by 90%, comparable with the effect of doxorubicin treatment with 81% inhibition of tumor growth. [1]

Protocol

Kinase Assay:

[1]

+ Expand

Biacore study:

Competition assay is performed on a Biacore S51. A Series S Sensor chip CM5 is utilized for the immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~200 response units (1 response unit corresponds to 1 pg of protein per mm2). The concentration of MDM2 protein is kept constant at 300 nM. Nutlin-3 is dissolved in DMSO at 10 mM and further diluted to make a concentration series of Nutlin-3 in each MDM2 test sample. The assay is run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of Nutlin-3 is calculated as a percentage of binding in the absence of Nutlin-3 and IC50 is calculate
Cell Research:

[1]

+ Expand
  • Cell lines: HCT116, RKO, SJSA-1, SW480, and MDA-MB-435
  • Concentrations: Dissolved in DMSO, final concentrations ~ 30 μM
  • Incubation Time: 8, 24, and 48 hours
  • Method:

    Cells are exposed to various concentrations of Nutlin-3 for 8, 24 and 48 hours. The transcriptional levels of p21 and MDM2 genes are analyzed by real-time PCR, and protein levels by western blotting. Cell viability is measured by the MTT assay. Cell apoptosis is determined by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining with flow cytometry and fluorescence microscopy.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Athymic female nude mice (Nu/Nu-nuBR) injected subcutaneously with SJSA-1 cells
  • Formulation: Formulated in 2% Klucel, 0.5% Tween 80
  • Dosages: 200 mg/kg
  • Administration: Orally, twice a day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (171.96 mM)
Ethanol 30 mg/mL (51.59 mM)
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 581.5
Formula

C30H30Cl2N4O4

CAS No. 890090-75-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is this a racemic mixture of Nutlin-3a and Nutlin-3b or just the Nutlin-3a enantiomer?

  • Answer:

    It is a racemate.

Mdm2 Signaling Pathway Map

Related Mdm2 Products0

Tags: buy Nutlin-3 | Nutlin-3 supplier | purchase Nutlin-3 | Nutlin-3 cost | Nutlin-3 manufacturer | order Nutlin-3 | Nutlin-3 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID